Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
- Conditions
- Portal HypertensionCirrhosisHematemesisMelena
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 320
- Registration Number
- NCT00534677
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sindh, Pakistan
Continuous Infusion of Terlipressin in Septic Shock
- Conditions
- Septic Shock
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2008-02-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 45
- Registration Number
- NCT00481572
- Locations
- 🇮🇹
Department of Anesthesiology and Intensive care of the University of Rome "La Sapienza", Rome, Viale del Policlinico 155, Italy
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 20
- Registration Number
- NCT00370253
- Locations
- 🇮🇹
San Giovanni Battista Hospital, Turin, Italy
Short Course Terlipressin for Control of Acute Variceal Bleeding
- Conditions
- HemorrhageEsophageal VaricesPortal Hypertension
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 130
- Registration Number
- NCT00369694
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sindh, Pakistan
Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
- Conditions
- CirrhosisHepatorenal Syndrome
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2007-04-11
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 100
- Registration Number
- NCT00287664
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
- Conditions
- CirrhosisAscites
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2006-03-09
- Lead Sponsor
- Hvidovre University Hospital
- Registration Number
- NCT00115947
- Locations
- 🇩🇰
Hvidovre Hospital, Copenhagen, Hvidovre, Denmark
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 112
- Registration Number
- NCT00089570
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Medicine & Dentistry of New Jersey - NJMS, Newark, New Jersey, United States
🇺🇸Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.